Page 57 - Read Online

Page 10 of 10 Inoue et al. Vessel Plus 2021;5:11 I http://dx.doi.org/10.20517/2574-1209.2020.99

insights from the DEFUSE-EPITHET pooled data set. Stroke 2011;42:1270-5.
33. Inoue M, Mlynash M, Straka M, et al. Patients with the malignant profile within 3 hours of symptom onset have very poor outcomes after
intravenous tissue-type plasminogen activator therapy. Stroke 2012;43:2494-6.
34. Lansberg MG, Christensen S, Kemp S, et al; CT Perfusion to Predict Response to Recanalization in Ischemic Stroke Project (CRISP)
Investigators. Computed tomographic perfusion to predict response to recanalization in ischemic stroke. Ann Neurol 2017;81:849-56.
35. Albers GW, Marks MP, Kemp S, et al; DEFUSE 3 Investigators. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion
imaging. N Engl J Med 2018;378:708-18.
36. Powers WJ, Rabinstein AA, Ackerson T, et al; American Heart Association Stroke Council. 2018 guidelines for the early management
of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke
Association. Stroke 2018;49:e46-e110.
37. Nogueira RG, Jadhav AP, Haussen DC, et al; DAWN Trial Investigators. Thrombectomy 6 to 24 hours after stroke with a mismatch
between deficit and infarct. N Engl J Med 2018;378:11-21.
38. Thomalla G, Simonsen CZ, Boutitie F, et al; WAKE-UP Investigators. MRI-guided thrombolysis for stroke with unknown time of onset.
N Engl J Med 2018;379:611-22.
39. Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with
alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014;384:1929-35.
40. Kang DW, Sohn SI, Hong KS, et al. Reperfusion therapy in unclear-onset stroke based on MRI evaluation (RESTORE): a prospective
multicenter study. Stroke 2012;43:3278-83.
41. Koton S, Tanne D, Bornstein NM; NASIS Investigators. Ischemic stroke on awakening: patients’ characteristics, outcomes and potential
for reperfusion therapy. Neuroepidemiology 2012;39:149-53.
42. Thomalla G, Rossbach P, Rosenkranz M, et al. Negative fluid-attenuated inversion recovery imaging identifies acute ischemic stroke at 3
hours or less. Ann Neurol 2009;65:724-32.
43. Toni D, Lorenzano S, Puca E, Prencipe M. The SITS-MOST registry. Neurol Sci 2006;27 Suppl 3:S260-2.
44. Koga M, Yamamoto H, Inoue M, et al; THAWS Trial Investigators. Thrombolysis with Alteplase at 0.6 mg/kg for stroke with unknown
time of onset: a randomized controlled trial. Stroke 2020;51:1530-8.
45. Toyoda K, Koga M, Iguchi Y, et al. Guidelines for intravenous thrombolysis (recombinant tissue-type plasminogen activator), the third
edition, March 2019: a guideline from the Japan Stroke Society. Neurol Med Chir (Tokyo) 2019;59:449-91.
46. Toyoda K, Inoue M, Yoshimura S, et al; THAWS trial investigators*. Magnetic resonance imaging-guided thrombolysis (0.6 mg/kg) was
beneficial for unknown onset stroke above a certain core size: THAWS RCT substudy. Stroke 2021;52:12-9.
47. Thomalla G, Boutitie F, Ma H, et al. Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic
review and meta-analysis of individual patient data. Lancet 2020;396:1574-84.
48. Ma H, Campbell BCV, Parsons MW, et al; EXTEND Investigators. Thrombolysis guided by perfusion imaging up to 9 hours after onset
of stroke. N Engl J Med 2019;380:1795-803.
49. Campbell BCV, Ma H, Ringleb PA, et al. Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic
review and meta-analysis of individual patient data. Lancet 2019;394:139-47.